-
Infant Microbiome Atlas Makes Case for Region-Specific Probiotics
Bio-IT World | When it comes to the microbiome, “our bodies are beautifully designed for a world that no longer exists." The bugs inhabiting our gut are a good match for high-fiber, plant-based dietary habits that have been largely replaced by processed foods that are killing off health-promoting bacteria and allowing more harmful varieties to dominate.
Mar 5, 2026
-
MIT Develops Biodegradable “Smart Pill” to Track Medication Adherence
Bio-IT World | Medication nonadherence has long been one of healthcare’s most stubborn problems. Roughly half of patients with chronic conditions do not take their medications as prescribed, according to the World Health Organization. This problem undermines treatment, fuels drug resistance, and costs the U.S. healthcare system hundreds of billions of dollars each year. However, engineers at MIT might be able to offer a new way forward.
Mar 4, 2026
-
Lee Hood’s Persistent Plan to Reinvent Medicine From the Ground Up
Bio-IT World | When Leroy Hood stepped up to the podium at last week's Integrative Healthcare Symposium to accept the Visionary Award, he told the audience he had done 200 push-ups before coming downstairs that morning. He is 87 years old. It was a fitting opening for a talk that was equal parts intellectual autobiography, scientific tour de force, and provocation—a challenge to an entire healthcare system that Hood believes is looking at the problem of human health almost entirely backwards.
Mar 3, 2026
-
Illumina Acquires SomaLogic, Sanofi’s New CEO, Parse Bioscience’s New Product Line
Bio-IT World | Illumina completes its acquisition of SomaLogic; Sanofi appoints Belén Garijo as chief executive officer; Parse Biosciences launches the new Evercode Whole Transcriptome v4 product line; and more.
Feb 26, 2026
-
Follow the Money: International Expansion for Cell Therapies, BPZE1 Pertussis Vaccine, Next-Gen AI De Novo Antibody Design
Bio-IT World | Cellares expands across different countries to commercially launch and manufacture cell therapies; ILiAD Biotechnologies advances their next generation pertussis vaccine candidate, BPZE1; Galux develops next-gen AI that goes beyond binder design to incorporate functional activity and developability; and more.
Feb 25, 2026


